Yifeng Pharmacy Chain Crescita futura

Future criteri di controllo 2/6

Yifeng Pharmacy Chain prevede che gli utili e i ricavi cresceranno rispettivamente di 17.7% e 15.1% all'anno. Si prevede che l'EPS crescerà di 18.6% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 19.8% in 3 anni.

Informazioni chiave

17.7%

Tasso di crescita degli utili

18.6%

Tasso di crescita dell'EPS

Consumer Retailing crescita degli utili	42.2%
Tasso di crescita dei ricavi	15.1%
Rendimento futuro del capitale proprio	19.8%
Copertura analitica	Good
Ultimo aggiornamento	19 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We Like The Quality Of Yifeng Pharmacy Chain's (SHSE:603939) Earnings

Nov 06

The Market Lifts Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Shares 28% But It Can Do More

Sep 27

Investors Met With Slowing Returns on Capital At Yifeng Pharmacy Chain (SHSE:603939)

Jul 29

Slammed 27% Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Screens Well Here But There Might Be A Catch

Jun 20

Yifeng Pharmacy Chain (SHSE:603939) Seems To Use Debt Rather Sparingly

May 24

Yifeng Pharmacy Chain's (SHSE:603939) Solid Earnings Are Supported By Other Strong Factors

May 06

Is Now The Time To Put Yifeng Pharmacy Chain (SHSE:603939) On Your Watchlist?

Apr 13

Market Participants Recognise Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Earnings

Mar 28

Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Intrinsic Value Is Potentially 100% Above Its Share Price

Mar 13

Previsioni di crescita degli utili e dei ricavi

SHSE:603939 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	33,761	2,310	3,592	4,416	16
12/31/2025	28,995	1,918	3,066	3,810	17
12/31/2024	24,224	1,584	2,034	2,788	11
9/30/2024	23,919	1,523	4,287	5,084	N/A
6/30/2024	23,644	1,505	4,261	5,038	N/A
3/31/2024	23,293	1,482	3,173	3,985	N/A
12/31/2023	22,588	1,412	3,884	4,624	N/A
9/30/2023	22,427	1,437	3,989	4,494	N/A
6/30/2023	21,843	1,391	3,690	4,235	N/A
3/31/2023	21,004	1,330	4,037	4,561	N/A
12/31/2022	19,886	1,262	3,333	3,920	N/A
9/30/2022	17,736	1,016	2,090	2,792	N/A
6/30/2022	16,730	960	1,572	2,265	N/A
3/31/2022	15,845	919	1,400	2,203	N/A
12/31/2021	15,326	888	1,322	2,150	N/A
9/30/2021	14,646	867	1,670	2,381	N/A
6/30/2021	14,198	847	1,710	2,434	N/A
3/31/2021	13,726	798	1,812	2,486	N/A
12/31/2020	13,145	744	1,747	2,330	N/A
9/30/2020	12,324	698	1,490	1,994	N/A
6/30/2020	11,521	637	914	1,404	N/A
3/31/2020	10,855	583	743	1,203	N/A
12/31/2019	10,276	544	504	963	N/A
9/30/2019	9,636	526	399	774	N/A
6/30/2019	8,968	499	435	768	N/A
3/31/2019	7,900	463	344	604	N/A
12/31/2018	6,913	416	267	511	N/A
9/30/2018	6,054	402	172	394	N/A
6/30/2018	5,562	384	N/A	359	N/A
3/31/2018	5,211	345	N/A	345	N/A
12/31/2017	4,807	314	N/A	317	N/A
9/30/2017	4,480	285	N/A	205	N/A
6/30/2017	4,210	267	N/A	193	N/A
3/31/2017	3,978	241	N/A	161	N/A
12/31/2016	3,734	224	N/A	140	N/A
9/30/2016	3,540	210	N/A	207	N/A
6/30/2016	3,305	200	N/A	195	N/A
3/31/2016	3,040	187	N/A	160	N/A
12/31/2015	2,846	176	N/A	182	N/A
9/30/2015	2,615	169	N/A	229	N/A
6/30/2015	2,492	161	N/A	192	N/A
3/31/2015	2,373	150	N/A	235	N/A
12/31/2014	2,230	141	N/A	212	N/A
12/31/2013	1,804	99	N/A	157	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 603939 ( 17.7% all'anno) è superiore al tasso di risparmio ( 2.8% ).

Guadagni vs Mercato: Si prevede che gli utili di 603939 ( 17.7% all'anno) cresceranno più lentamente rispetto al mercato CN ( 26.2% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 603939 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 603939 ( 15.1% all'anno) crescerà più rapidamente del mercato CN ( 13.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 603939 ( 15.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 603939 sarà basso tra 3 anni ( 19.8 %).

Yifeng Pharmacy Chain Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 8.0% to CN¥39.55

Price target decreased by 15% to CN¥45.15

Price target decreased to CN¥64.76

Price target decreased to CN¥69.45

Price target decreased to CN¥68.15

Price target raised to CN¥104

Recent updates

We Like The Quality Of Yifeng Pharmacy Chain's (SHSE:603939) Earnings

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 18%

Yifeng Pharmacy Chain Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

The Market Lifts Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Shares 28% But It Can Do More

Investor sentiment improves as stock rises 24%

Price target decreased by 8.0% to CN¥39.55

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Investors Met With Slowing Returns on Capital At Yifeng Pharmacy Chain (SHSE:603939)

Yifeng Pharmacy Chain Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Slammed 27% Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Screens Well Here But There Might Be A Catch

Price target decreased by 15% to CN¥45.15

Investor sentiment deteriorates as stock falls 19%

Yifeng Pharmacy Chain (SHSE:603939) Seems To Use Debt Rather Sparingly

Yifeng Pharmacy Chain's (SHSE:603939) Solid Earnings Are Supported By Other Strong Factors

Full year 2023 earnings released: EPS: CN¥1.40 (vs CN¥1.26 in FY 2022)

Yifeng Pharmacy Chain Co., Ltd., Annual General Meeting, May 20, 2024

Is Now The Time To Put Yifeng Pharmacy Chain (SHSE:603939) On Your Watchlist?

Yifeng Pharmacy Chain Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Market Participants Recognise Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Earnings

Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Intrinsic Value Is Potentially 100% Above Its Share Price

Yifeng Pharmacy Chain Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Yifeng Pharmacy Chain Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment deteriorates as stock falls 33%

Now 20% undervalued after recent price drop

Less than half of directors are independent

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) completed the acquisition of a 51% stake in Hunan Jiuzhitang Pharmaceutical Co., Ltd. from Jiuzhitang Co., Ltd. (SZSE:000989).

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥64.76

Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) agreed to acquire 5% stake in Jiuzhitang Co., Ltd. (SZSE:000989) from Li Zhenguo for CNY 430 million.

Less than half of directors are independent

Investor sentiment improved over the past week

Price target decreased to CN¥69.45

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.25 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.32 in 2Q 2020)

Investor sentiment improved over the past week

Price target decreased to CN¥68.15

First quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.35 in 1Q 2020)

New 90-day low: CN¥88.10

Investor sentiment improved over the past week

New 90-day low: CN¥88.50

Price target raised to CN¥104

New 90-day high: CN¥107

Third quarter earnings released

Yifeng Pharmacy Chain Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

First half earnings released

New 90-day high - CN¥97.54

Yifeng Pharmacy Chain Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita